title: The effect of drugs used in the treatment of osteoarthrosis on stromelysin (proteoglycanase) of equine synovial cell origin.
abstract: There is increasing evidence that the proteoglycan-degrading neutral metalloproteinase, stromelysin, is a key enzyme in the pathogenesis of osteoarthrosis. Equine synovial lining cells were stimulated in vitro to produce stromelysin, and phenylbutazone, flunixin, betamethasone, sodium hyaluronate and polysulphated glycosaminoglycan (PSGAG) were tested for their ability to inhibit the action of this enzyme on 14C-labelled casein substrate. Only PSGAG possessed inhibitory activity at concentrations likely to be achieved therapeutically in the equine fetlock joint.
authors.affiliation: Department of Veterinary Basic Sciences, Royal Veterinary College, North Mymms, Hatfield, Herts.
authors.forename: S A
authors.initials: SA
authors.lastname: May
authors.forename: R E
authors.initials: RE
authors.lastname: Hooke
authors.forename: P
authors.initials: P
authors.lastname: Lees
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001623:Betamethasone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D003002:Clonixin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D006025:Glycosaminoglycans / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006734:Horse Diseases / Q000188:drug therapy* / Q000201:enzymology*; D006736:Horses; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D019278:Matrix Metalloproteinase 3 / Q000187:drug effects* / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors; D010003:Osteoarthritis / Q000188:drug therapy / Q000201:enzymology / Q000662:veterinary*; D010653:Phenylbutazone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D010662:Phenylmercuric Acetate / Q000031:analogs & derivatives / Q000494:pharmacology; D014357:Trypsin / Q000494:pharmacology
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D006025:Glycosaminoglycans; D061965:Matrix Metalloproteinase Inhibitors; C013786:A73025; C014557:flunixin; C010024:4-aminophenylmercuriacetate; D006820:Hyaluronic Acid; D001623:Betamethasone; D014357:Trypsin; D019278:Matrix Metalloproteinase 3; D010653:Phenylbutazone; D010662:Phenylmercuric Acetate; D003002:Clonixin